Drug-drug interactions of warfarin and new direct oral anticoagulans

Michal Prokeš, Josef Suchopár

Prakt. Lékáren. 2019; 15(1e): 15-35  

Anticoagulation therapy with warfarin and direct oral anticoagulants annually saves lives of many patients. These patients often take medicinesthat change the effect of anticoagulants. This article attempts to present in a synopical way information about such interactions that physiciansprescribe. Although warfarin has more interactions than DOAC, some DOAC interactions are equally dangerous and, unlike warfarin, theeffect of DOAC cannot be easily monitored. This may be a problem because there are patients in whom the drug interaction is more intense than in average patients, for example when dabigatran is combined with clarithromycin.

Latest developments in the management of resistant hypertension

Renata Cífková

Prakt. Lékáren. 2019; 15(1e): 36-40  

Hypertension resistant to treatment is currently defined as a situation when the recommended treatment strategy fails to lower office bloodpressure to values < 140/90 mmHg, and inadequate control of blood pressure is confirmed by ambulatory blood pressure monitoring or homeblood pressure measurement. The recommended treatment strategy should include treatment with optimal or best-tolerated doses of three or more drugs that should include a diuretic and, typically, an ACE inhibitor or angiotensin receptor blocker and a calcium-channel blocker. Theestimated prevalence using the above definition is likely to be < 10% of treated...

Antiparkinsonian drugs, mental disorders in patients with Parkinson’s disease and drug -drug interactions

Michal Prokeš, Josef Suchopár

Prakt. Lékáren. 2019; 15(1e): 41-53  

Patients with Parkinson´s disease (PN), a common neurodegenerative disorder, suffer not only from movement disorder, but also from mentaldisorders including behavioral disorders and psychosis. These disorders are closely related to dopaminergic treatment of PN. Despite knowledgeof the clinical features of these disorders, many patients may not be diagnosed in time. Another issue are drug-drug interactions, because patients with PN are treated for associated diseases usually by other physicians, who may not always be aware, that the antiparkinsonian orantipsychotic drugs interact with other commonly prescribed drugs. This article introduces...

Brexpiprazole

Miloslav Kopeček

Prakt. Lékáren. 2019; 15(1e) | DOI: 10.36290/lek.2019.023  

Brexpiprazole is a second generation antipsychotic that works as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors and an antagonistat serotonin 5-HT2A. Brexpiprazole showed efficacy for the treatment of schizophrenia in the range of 2 to 4 mg/d and as an adjunct toantidepressant therapy in major depressive disorder when dosed at 2 to 3 mg/d. It has European Medicines Agency approval for monotherapytreatment of adult schizophrenia but has not approval for adjunctive treatment to antidepressants for MDD as in USA. The most common adverse effects include akathisia and weight gain. Advantages of brexpiprazole include once...

Konjac – active compounds and therapeutic effects

Zdeňka Navrátilová

Prakt. Lékáren. 2019; 15(1e): e54-e59 | DOI: 10.36290/lek.2019.027  

Voodoo lilies (Amorphophallus spp.) are imposing herbs belonging to aroid family (Araceae). Some species are used in traditional Chinesemedicine for thousands of years, one of them is Amorphophallus konjac. Konjac tubers are used for treatment of many illnesses and also forfood purposes. Its therapeutic effects are discovered by Western medicine now; some of them were confirmed in clinical trials. Glucomannanisolated from konjac tubers has hypolidipidemic, laxative, anti-obesity, and antidiabetic properties and can be used as dietary supplementsuch as food component.

Nový výbor ČFS na roky 2019–2022

Prakt. Lékáren. 2019; 15(1e)  

Střípky z XX. sympozia klinické farmacie René Macha

Julie Zubrová, Anna Patková, Eva Zimčíková

Prakt. Lékáren. 2019; 15(1e): e64-e72  

Historický kalendář na rok 2019

Pavel Drábek

Prakt. Lékáren. 2019; 15(1e): e60-e63